Drug Delays Progression of Early-stage Arthritis

by Rajashri on  June 16, 2009 at 9:12 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

 Drug Delays Progression of Early-stage Arthritis
A new study presented at the EULAR conference says that rituximab is capable of completely halting the progression of rheumatoid arthritis (RA) in patients who show first signs of the disease.

The study on 755 patients found that when rituximab is used with methotrexate for a year, the signs of joint deterioration completely halted. Some 70% of patients treated with this regimen within six months of showing initial signs did not have any joint damage for over 122 months of therapy.

"The emphasis should be on the early stage of disease. When patients first develop the disease there is no joint damage and the aim is to prevent that happening. That's essentially what this combination is doing," leading rheumatologist Professor John Isaacs, of the Institute of Cellular Medicine at Newcastle University told the BBC.

Rituximab is not yet approved for use in early RA and it will be up to the National Institute for Health and Clinical Excellence to decide if it must be used early. Currently the drug is recommended only if treatment by other arthritis drugs called TNF do not halt joint damage in RA.



Source: Medindia
RAS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Oligoarthritis Signature Drug Toxicity Knee Replacement Reiterís syndrome Arthritis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive